Pfizer Covid Vaccine and T Cells By Brian Simpson
According to a study from the Francis Crick Institute in the United Kingdom, the Pfizer-BioNTech (COVID-19) vaccine destroys T cells and weakens the immune system. The suggested response to this is to receive more booster shots. That makes sense to me, for if something has caused a problem, applying more of that something must make things better, today’s standard solution. If smoking has caused your lung cancer, then smoking even more, will make everything alright, won’t it? It is only “logical.”
“A study from the Francis Crick Institute in the United Kingdom has found that the Pfizer-BioNTech Wuhan coronavirus (COVID-19) vaccine destroys T cells and weakens the immune system. But pharmaceutical corporations are trying to suggest that the only way to prevent this from happening is for people to get third or booster doses of their vaccines.
T cells are immune cells that can focus on targeting specific foreign particles. They are most commonly studied in relation to their ability to fight cancer and infectious diseases, but they are also essential for other aspects of the body’s immune response.
There are two kinds of T cells: killer T cells and helper T cells. Killer T cells directly attack cells that have already been infected by foreign particles. Helper T cells aid other cells to develop killer cells and stimulate other cells to create neutralizing antibodies.
This study from the Francis Crick Institute focuses on the neutralizing antibodies created by T cells. It analyzes whether the Pfizer vaccine helps the T cells create enough antibodies to fight off the COVID-19 variants.
Pfizer vaccine barely produces antibodies to fight against COVID-19.
The Francis Crick Institute, in collaboration with the British National Institute for Health Research, released a study that showed that the Pfizer-BioNTech COVID-19 vaccine produced fewer neutralizing antibodies against COVID-19’s variants.
The scientists analyzed the antibodies from the blood of 250 healthy adults who have received either one or two doses of the Pfizer-BioNTech vaccine up to three months after their first dose.
The researchers used a test specially developed by the Francis Crick Institute to figure out the ability of the neutralizing antibodies to prevent the entry of the COVID-19 variants.
It found that only 50 percent of the people who received a single dose of the Pfizer vaccine had a quantifiable neutralizing antibody response against the alpha variant of COVID-19. This number decreased even further to just 32 percent and 25 percent for the delta and beta variants, respectively.
The situation gets worse for older individuals who have weaker immune systems. The researchers found that older vaccine recipients generated even fewer antibodies. Coupled with the vaccine’s ability to destroy T cells and weaken the immune system even further, getting vaccinated could spell disaster for many people.
No correlation was observed for gender or body mass index. The authors of the study want to pursue further studies to check the capabilities of other vaccines, starting with the Oxford-AstraZeneca vaccine.
“So, the key message from our finding is we found that recipients of the Pfizer vaccine, those who have had two doses, have about five- to six-fold lower amounts of neutralizing antibodies,” said David Bauer, head of the Bauer Lab in the Francis Crick Institute. He continued:
“Now, these are the, sort of, gold standard, private security antibodies of your immune system which block the virus from getting into your cells in the first place. So, we’ve found that that is less for people with two doses. We also found that for people with only one dose of the Pfizer jab that they are less likely to have high levels of these antibodies in their blood.”
Instead of recommending that people stay away from the COVID-19 vaccines to protect their natural immune systems, Bauer instead said people should get booster doses of the vaccines. He also said older people should be prioritized in the distribution of booster doses.
“And perhaps most importantly for all of us going forward is that we see that the older you are, the lower your levels are likely to be. And the time since you’ve had your second jab, as that time goes on, the lower your levels are also likely to be,” he said. “So, that’s telling us that we are probably going to be needing to prioritize boosters for older and more vulnerable people.”
https://www.infowars.com/posts/studies-confirm-covid-injections-destroy-t-cells-immune-system/
“A study from the Francis Crick Institute in the United Kingdom and published as a research letter in “The Lancet” (one of the world’s oldest and best-known general medical journals) has found that the Pfizer-BioNTech coronavirus (Covid-19) vaccine creates lower antibody protection levels against the Delta variant than the original Wuhan strain.
The study also suggests that those with only one dose are less protected than those with two doses of the vaccine. The study did not consider the question of Pfizer and other laboratories urging people to get third or booster doses of their vaccines.
T cells are immune cells that can focus on targeting specific foreign particles. They are most commonly studied in relation to their ability to fight cancer and infectious diseases, but they are also essential for other aspects of the body’s immune response.
There are two kinds of T cells: killer T cells and helper T cells. Killer T cells directly attack cells that have already been infected by foreign particles. Helper T cells aid other cells to develop killer cells and stimulate other cells to create neutralizing antibodies.
This June 3 study from the Francis Crick Institute focuses on the neutralizing antibodies created by T cells. It analyzes whether the Pfizer vaccine helps the T cells create enough antibodies to fight off the various COVID-19 variants. A subsequent June 28 study by the Crick Institute includes tests of the antibody reaction from the AstraZeneca/Oxford vaccine.
PFIZER VACCINE UNDERPERFORMS AGAINST VARIANTS, PARTICULARLY THE DELTA.
The Francis Crick Institute, in collaboration with the British National Institute for Health Research, released a study on June 3 that showed that the Pfizer-BioNTech COVID-19 vaccine produced fewer neutralizing antibodies against COVID-19’s variants.
The scientists analyzed the antibodies from the blood of 250 healthy adults who have received either one or two doses of the Pfizer-BioNTech vaccine up to three months after their first dose.
The researchers used a test specially developed by the Francis Crick Institute to figure out the ability of the neutralizing antibodies to prevent the entry of the COVID-19 variants.
It found that only 50 percent of the people who received a single dose of the Pfizer vaccine had a quantifiable neutralizing antibody response against the Alpha variant of COVID-19. This number decreased even further to just 32 percent and 25 percent for the Delta and Beta variants, respectively.
The situation is worse for older individuals who have weaker immune systems. The researchers found that older vaccine recipients generated even fewer antibodies.
No correlation was observed for gender or body mass index. The authors of the June 3 study pursued further studies to check the capabilities of other vaccines, starting with the Oxford-AstraZeneca vaccine, which gave rise to the study published June 28.
“So, the key message from our finding is we found that recipients of the Pfizer vaccine, those who have had two doses, have about five- to six-fold lower amounts of neutralizing antibodies,” said David Bauer, head of the Bauer Lab in the Francis Crick Institute. He continued:
“Now, these are the sort of, gold standard, private security antibodies of your immune system which block the virus from getting into your cells in the first place. So, we’ve found that that is less for people with two doses. We also found that for people with only one dose of the Pfizer jab that they are less likely to have high levels of these antibodies in their blood.”
Instead of recommending that people stay away from the Covid-19 vaccines to protect their natural immune systems, Bauer instead said people should get booster doses of the vaccines. He also said older people should be prioritized in the distribution of booster doses.”
“Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Thursday) as a Research letter in The Lancet.
The results also show that levels of these antibodies are lower with increasing age and that levels decline over time, providing additional evidence in support of plans to deliver a vaccination boost to vulnerable people in the Autumn.
And, the researchers support current plans to reduce the dose gap between vaccines since they found that after just one dose of the Pfizer-BioNTech vaccine, people are less likely to develop antibody levels against the B.1.617.2 (Delta) variant as high as those seen against the previously dominant B.1.1.7 (Alpha) variant, first found in Kent.
This work is a powerful example of effective collaborations between NHS and academic colleagues, that can help us to navigate changes in this new phase of the pandemic. David LV Bauer
Although laboratory results such as these are needed to provide a guide as to how the virus might be evolving to escape the first generation of vaccines, levels of antibodies alone do not predict vaccine effectiveness and prospective population studies are also needed. Lower neutralising antibody levels may still be associated with protection against COVID-19.
This is the largest study published to date investigating vaccine-induced antibody neutralising capacity against the newest variants of concern in healthy adults. Researchers have submitted their findings to the Genotype-to-Phenotype National Virology Consortium (G2P-UK), the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) and the Joint Committee on Vaccination and Immunisation (JCVI), as evidence of the level of protection people might receive against the new variants after one dose and both doses of the Pfizer COVID-19 vaccine.
As part of the SARS-CoV-2 Legacy study, led by the Crick and partners at UCL and University College London Hospitals NHS Foundation Trust (UCLH), healthcare workers and staff from the institutions have been donating regular blood and swab samples so that researchers can track changing risk of infection and response to vaccination.
Thanks to samples of the latest variants of concern being provided by NHS labs to the G2P-UK consortium, researchers have been able to quickly assess the potential risks they might pose.
Within just a few days of having enough of each variant to study, they were able to analyse antibodies in the blood of 250 healthy people who received either one or two doses of the Pfizer-BioNTech Covid-19 vaccine, up to three months after their first dose. Using a new highly accurate high throughput viral neutralisation assay developed at the Crick, they tested the ability of antibodies to block entry of the virus into cells, so called ‘neutralising antibodies’, against five different variants of SARS-CoV-2:
- The original strain first discovered in Wuhan, China
- The dominant strain in Europe during the first wave in April 2020 (D614G)
- 1.1.7, the variant first discovered in Kent, UK (Alpha)
- 1.351, the variant first discovered in South Africa (Beta)
- 1.617.2, the newest variant of concern, first discovered in India (Delta)
They then compared concentrations of these neutralising antibodies between all variants. Data from previous clinical studies suggests that higher antibody titres (the greatest dilution level that still blocks 50% of virus infection in the lab) is a good predictor of vaccine efficacy and greater protection against COVID-19.
They found that in people who had been fully vaccinated with two doses of the Pfizer-BioNTech vaccine, levels of neutralising antibodies were more than five times lower* against the B.1.617.2 variant when compared to the original strain, upon which current vaccines are based.
Importantly, this antibody response was even lower in people who had only received one dose. After a single dose of Pfizer-BioNTech, 79% of people had a quantifiable neutralising antibody response against the original strain, but this fell to 50% for B.1.1.7, 32% for B.1.617.2 and 25% for B.1.351.
While antibody levels decreased with age against all variants, no correlation was observed for sex or BMI.
Featured teams:
- Francis Crick Institute
- National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre
- Clinical Research Facility, at NIHR UCLH
- University College London
- Department of Infectious Disease, St Mary’s Hospital, Imperial College London
The study participants analysed here had all been vaccinated with the Pfizer-BioNTech vaccine. More work is underway to test neutralising antibodies against these same variants in people who have been vaccinated with the Oxford/AstraZeneca vaccine.
Emma Wall, UCLH Infectious Diseases consultant and Senior Clinical Research Fellow for the Legacy study, said: “This virus will likely be around for some time to come, so we need to remain agile and vigilant. Our study is designed to be responsive to shifts in the pandemic so that we can quickly provide evidence on changing risk and protection.
“The most important thing is to ensure that vaccine protection remains high enough to keep as many people out of hospital as possible. And our results suggest that the best way to do this is to quickly deliver second doses and provide boosters to those whose immunity may not be high enough against these new variants.”
David LV Bauer, group leader of the Crick’s RNA Virus Replication Laboratory and member of the G2P-UK National Virology Consortium, said: “New variants occur naturally and those that have an advantage will spread. We now have the ability to quickly adapt our vaccination strategies to maximise protection where we know people are most vulnerable.
“Keeping track of these evolutionary changes is essential for us to retain control over the pandemic and return to normality. This work is a powerful example of effective collaborations between NHS and academic colleagues, that can help us to navigate changes in this new phase of the pandemic.”
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01290-3/fulltext
Comments